Sudden Sensorineural Hearing Loss with a Small Enhancing IAC Lesion
A 47-year-old woman presents with sudden left-sided hearing loss and tinnitus over 3 days, with no vertigo and no facial weakness. Audiometry shows left moderate-to-severe sensorineural loss. MRI with contrast shows a 4 mm enhancing nodule in the left internal auditory canal fundus on the facial/vestibular nerve bundle, with no intracanalicular extension beyond the fundus and no brainstem involvement. The radiologist's report calls it 'suspicious for vestibular schwannoma versus other enhancing lesion.' The ENT team is planning high-dose steroids for presumed sudden SNHL and asks whether the MRI changes management.
1. What is the differential for a small enhancing IAC fundus lesion, and why does sudden SNHL complicate the read?
Read the worked answer
Differential for a small enhancing IAC lesion:
- Vestibular schwannoma (most common; usually centered on the vestibular nerve, often with intracanalicular extension and 'ice cream cone' appearance).
- Facial nerve schwannoma (centered on CN VII, often with facial symptoms - absent here).
- Meningioma (usually broad-based, dural tail, eccentric in the canal).
- Inflammatory/immune neuritis (e.g., Bell's palsy spectrum, sarcoid, Lyme) - can enhance and cause sudden SNHL.
- Metastasis or lymphoma (rare, but consider if rapid progression).
Sudden SNHL complicates the read because sudden SNHL itself can cause nerve enhancement from inflammation, and conversely a small schwannoma can present as sudden SNHL. A 4 mm fundus nodule is at the size where schwannoma and inflammatory enhancement overlap, and a single study cannot reliably separate them.
2. Should the MRI change the immediate management of presumed sudden SNHL? Justify your answer.
Read the worked answer
No - it should not delay steroids. Sudden SNHL is a time-sensitive diagnosis; high-dose corticosteroids (or intratympanic steroids) should start promptly regardless of a small enhancing lesion, because the dominant treatable cause is inflammatory/viral and delay worsens prognosis. The 4 mm nodule is small and does not change the acute treatment.
What the MRI does change is the follow-up plan: rather than treating this as a one-off and discharging, you now need a dedicated follow-up MRI (typically 3–6 months) with thin-section heavily T2-weighted and post-contrast IAC sequences to see whether the nodule persists, grows, or resolves. Resolution supports inflammatory neuritis; persistence/growth supports schwannoma. Also ensure the audiogram is repeated and consider vestibular testing.
3. What follow-up imaging protocol and decision points would you specify, and what would prompt intervention?
Read the worked answer
Protocol: repeat MRI in 3–6 months with thin-section (≤1 mm) heavily T2-weighted (FIESTA/CISS/DRIVE) plus post-contrast T1 of the IACs, same scanner and sequences for comparison. If stable or smaller, extend to annual imaging for 1–2 years; if resolved, no further imaging.
Decision points:
- Growth or new intracanalicular/brainstem extension → treat as vestibular schwannoma; discuss observation vs. stereotactic radiosurgery vs. microsurgery based on size, hearing status, and patient preference. At 4 mm, observation or radiosurgery is typical; surgery is reserved for larger or refractory cases.
- Stable small lesion with serviceable hearing → continued observation.
- Resolution → inflammatory neuritis; no further tumor workup.
- New facial weakness, vertigo, or rapid growth → expedite surgical/neuro-oncology input.
Also repeat audiometry at each visit and counsel the patient that the most likely outcome for a lesion this size is either resolution (if inflammatory) or a very slow-growing benign tumor.